46
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CRISPR/Cas9 for cancer research and therapy

      , , , ,
      Seminars in Cancer Biology
      Elsevier BV

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system, CRISPR/Cas9 and modified versions have found a widespread use to engineer genomes and to activate or to repress the expression of genes. As such, CRISPR/Cas9 promises to accelerate cancer research by providing an efficient technology to dissect mechanisms of tumorigenesis, identify targets for drug development, and possibly arm cells for cell-based therapies. Here, we review current applications of the CRISPR/Cas9 technology for cancer research and therapy. We describe novel Cas9 variants and how they are used in functional genomics to discover novel cancer-specific vulnerabilities. Furthermore, we highlight the impact of CRISPR/Cas9 in generating organoid and mouse models of cancer. Finally, we provide an overview of the first clinical trials that apply CRISPR/Cas9 as a therapeutic approach against cancer.

          Related collections

          Author and article information

          Journal
          Seminars in Cancer Biology
          Seminars in Cancer Biology
          Elsevier BV
          1044579X
          April 2018
          April 2018
          Article
          10.1016/j.semcancer.2018.04.001
          29673923
          5d35a684-0d86-4a71-a7af-e48a0ae361b0
          © 2018

          https://www.elsevier.com/tdm/userlicense/1.0/

          http://creativecommons.org/licenses/by/4.0/

          History

          Comments

          Comment on this article